N/A N=19 Other

FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis

Cholecystitis

Bottom Line

View on ClinicalTrials.gov: NCT00590395 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2019

Primary outcome: Primary: Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis — 9; 0; 1; 1 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: 18FDG (an FDA-approved radiopharmaceutical) (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Alan D. Waxman, M.D.
Primary completion: Jan 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Sensitivity and Specificity of FDG PET/CT and Tc99mHIDA in the Evaluation of Subjects Suspected of Cholecystitis	9; 0; 1; 1; 2; 6	—

Summary

This is a pilot study to investigate the ability of fluorodeoxyglucose-positron emission tomography (FDG-PET) and Positron emission tomography-computed tomography (PET/CT) as a direct method of detecting infection and/or inflammation of the gallbladder.

Eligibility Criteria

Inclusion Criteria

known or high suspicion of cholecystitis
highly likely to undergo cholecystectomy
positive HIDA study
age >18 years old
provide written informed consent

Exclusion Criteria

highly unlikely to proceed to surgery or biopsy
received an investigational drug within the past 30 days
pregnant or lactating
decline to provide written informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00590395). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.